XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 113,688 $ 155,700
Short-term investments 121,898 266,308
Accounts receivable, net ($6,079 and $12,088 from related parties) 12,553 16,299
Inventories 41,565 40,436
Prepaid expenses and other current assets 41,855 14,083
Total current assets 331,559 492,826
Restricted time deposits 1,658 2,072
Long-term investments 0 4,348
Property and equipment, net 13,126 20,605
Equity method investment in unconsolidated variable interest entity 5,290 5,061
Operating lease right-of-use assets 68,093 79,893
Other assets 3,803 5,282
Total assets 423,529 610,087
Current liabilities:    
Accounts payable 17,960 30,758
Accrued and other current liabilities ($39,814 and $63,886 to a related party) 172,891 219,773
Deferred revenue ($7,220 and $9,259 to related parties) 12,740 12,739
Operating lease liabilities, current 14,077 10,292
Total current liabilities 217,668 273,562
Product development obligations 17,763 16,917
Deferred revenue, net of current ($9,705 and $31,044 to a related party) 157,555 185,722
Operating lease liabilities, non-current 66,537 79,593
Senior secured term loan facilities, non-current 71,934 0
Liability related to sale of future revenues, non-current 51,413 49,333
Other long-term liabilities ($656 and $0 to a related party) 2,858 6,440
Total liabilities 585,728 611,567
Commitments and Contingencies (Note 12)  
Redeemable non-controlling interests 21,480 0
Stockholders' deficit:    
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022
Common stock, $0.01 par value; 225,000 shares authorized at December 31, 2023 and 2022; 98,770 and 94,166 shares issued and outstanding at December 31, 2023 and 2022 988 942
Additional paid-in capital 1,643,641 1,541,019
Accumulated other comprehensive loss (6,875) (5,720)
Accumulated deficit (1,841,920) (1,557,688)
Total stockholders' deficit attributable to FibroGen (204,166) (21,447)
Nonredeemable non-controlling interests 20,487 19,967
Total deficit (183,679) (1,480)
Total liabilities, redeemable non-controlling interests and deficit $ 423,529 $ 610,087